Product Name: MARK1-ANT
Product Number: AB-NK098-2
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: MAP/microtubule affinity-regulating protein-serine kinase 1
Target Alias: KIAA1477; MAP/microtubule affinity-regulating kinase 1; MARK
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK098-2
Antibody Target Type: Pan-specific
Protein UniProt: Q9P0L2
Protein SigNET: Q9P0L2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MARK1 sequence peptide Cat. No.: PE-01BDQ90
Antibody Immunogen Sequence: YTEPHIQPTKSSSRQNIPRC
Target Alias: KIAA1477; MAP/microtubule affinity-regulating kinase 1; MARK
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK098-2
Antibody Target Type: Pan-specific
Protein UniProt: Q9P0L2
Protein SigNET: Q9P0L2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MARK1 sequence peptide Cat. No.: PE-01BDQ90
Antibody Immunogen Sequence: YTEPHIQPTKSSSRQNIPRC
Antibody Immunogen Description: Corresponds to amino acid residues Y24 to C43; Post-N-terminus
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 85-90 kDa.
Related Product 1: MARK1-ANT blocking peptide
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 85-90 kDa.
Related Product 1: MARK1-ANT blocking peptide
Related Product 2: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK694)
Related Product 3: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK695)
Related Product 5: MARK2-ANT pan-specific antibody (Cat. No.: AB-NK275-1)
Related Product 6: MARK2-BCT pan-specific antibody (Cat. No.: AB-NK275-2)
Related Product 7: MARK3-ANT pan-specific antibody (Cat. No.: AB-NK276-1)
Related Product 8: MARK3-BCT pan-specific antibody (Cat. No.: AB-NK276-2)
Related Product 9: MARK3-pT507 phosphosite-specific antibody (Cat. No.: AB-PK697)
Related Product 10: MARK4-ANT pan-specific antibody (Cat. No.: AB-NK277-1)
Related Product 3: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK695)
Related Product 5: MARK2-ANT pan-specific antibody (Cat. No.: AB-NK275-1)
Related Product 6: MARK2-BCT pan-specific antibody (Cat. No.: AB-NK275-2)
Related Product 7: MARK3-ANT pan-specific antibody (Cat. No.: AB-NK276-1)
Related Product 8: MARK3-BCT pan-specific antibody (Cat. No.: AB-NK276-2)
Related Product 9: MARK3-pT507 phosphosite-specific antibody (Cat. No.: AB-PK697)
Related Product 10: MARK4-ANT pan-specific antibody (Cat. No.: AB-NK277-1)
Scientific Background: MARK1 is a protein-serine/threonine kinase that is is a member of the CAMK group of protein kinases in the CAMKL family, and MARK subfamily. It mediates control of cell polarity and microtubule function. This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. It is activated by phosphorylation on T215 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. MARK1 phosphorylates microtubule-associated proteins and trigger microtubule disruption. Gene mutation studies performed in mice revealed that after targeted disruption of the MARK1 gene, the mice lacked the ability to drink, and displayed hind leg motor dysfunction. Genetic variations in MARK1 have been correlated with susceptibility to autism. MARK1 is over-expressed in the prefrontal cortex of autism patients and affects the function of cortical dendrites. MARK1 has also been linked with the development of gastric adenocarcinomas and ovarian serous carcinomas.
© Kinexus Bioinformatics Corporation 2017